Literature DB >> 23219563

Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries.

Christophe Morisseau1, Sunil Sahdeo, Gino Cortopassi, Bruce D Hammock.   

Abstract

The EPXH2 gene encodes soluble epoxide hydrolase (sEH), which has two distinct enzyme activities: epoxide hydrolase (Cterm-EH) and phosphatase (Nterm-phos). The Cterm-EH is involved in the metabolism of arachidonic acid epoxides that play important roles in blood pressure, cell growth, inflammation, and pain. While recent findings suggested complementary biological roles for Nterm-phos, research is limited by the lack of potent bioavailable inhibitors of this phosphatase activity. Also, a potent bioavailable inhibitor of this activity could be important in the development of therapy for cardiovascular diseases. We report herein the development of an HTS enzyme-based assay for Nterm-phos (Z'>0.9) using AttoPhos as the substrate. This assay was used to screen a wide variety of chemical entities, including a library of known drugs that have reached through clinical evaluation (Pharmakon 1600), as well as a library of pesticides and environmental toxins. We discovered that ebselen inhibits sEH phosphatase activity. Ebselen binds to the N-terminal domain of sEH (K(I)=550 nM) and chemically reacts with the enzyme to quickly and irreversibly inhibit Nterm-phos, and subsequently Cterm-EH, and thus represents a new class of sEH inhibitor.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219563      PMCID: PMC3557602          DOI: 10.1016/j.ab.2012.11.017

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  38 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Inflammatory lipid mediators in adipocyte function and obesity.

Authors:  Abishek Iyer; David P Fairlie; Johannes B Prins; Bruce D Hammock; Lindsay Brown
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

3.  Redox regulation of soluble epoxide hydrolase by 15-deoxy-delta-prostaglandin J2 controls coronary hypoxic vasodilation.

Authors:  Rebecca L Charles; Joseph R Burgoyne; Manuel Mayr; Steven M Weldon; Norbert Hubner; Hua Dong; Christophe Morisseau; Bruce D Hammock; Aimee Landar; Philip Eaton
Journal:  Circ Res       Date:  2010-12-16       Impact factor: 17.367

4.  Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids.

Authors:  Christophe Morisseau; Bora Inceoglu; Kara Schmelzer; Hsing-Ju Tsai; Steven L Jinks; Christine M Hegedus; Bruce D Hammock
Journal:  J Lipid Res       Date:  2010-07-27       Impact factor: 5.922

Review 5.  The soluble epoxide hydrolase as a pharmaceutical target for hypertension.

Authors:  Nipavan Chiamvimonvat; Chin-Min Ho; Hsing-Ju Tsai; Bruce D Hammock
Journal:  J Cardiovasc Pharmacol       Date:  2007-09       Impact factor: 3.105

6.  Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth.

Authors:  Ami Oguro; Koichi Sakamoto; Sachiko Suzuki; Susumu Imaoka
Journal:  Biol Pharm Bull       Date:  2009-12       Impact factor: 2.233

7.  The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase.

Authors:  Annette Cronin; Sherry Mowbray; Heike Dürk; Shirli Homburg; Ingrid Fleming; Beate Fisslthaler; Franz Oesch; Michael Arand
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

8.  Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives.

Authors:  C Morisseau; G Du; J W Newman; B D Hammock
Journal:  Arch Biochem Biophys       Date:  1998-08-15       Impact factor: 4.013

Review 9.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

10.  Toxicology in the fast lane: application of high-throughput bioassays to detect modulation of key enzymes and receptors.

Authors:  Christophe Morisseau; Oleg Merzlikin; Amy Lin; Guochun He; Wei Feng; Isela Padilla; Michael S Denison; Isaac N Pessah; Bruce D Hammock
Journal:  Environ Health Perspect       Date:  2009-07-31       Impact factor: 9.031

View more
  11 in total

1.  Inhibiting an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa Protects CFTR.

Authors:  Christopher D Bahl; Kelli L Hvorecny; Jennifer M Bomberger; Bruce A Stanton; Bruce D Hammock; Christophe Morisseau; Dean R Madden
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-01       Impact factor: 15.336

2.  Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.

Authors:  Jan S Kramer; Stefano Woltersdorf; Thomas Duflot; Kerstin Hiesinger; Felix F Lillich; Felix Knöll; Sandra K Wittmann; Franca-M Klingler; Steffen Brunst; Apirat Chaikuad; Christophe Morisseau; Bruce D Hammock; Carola Buccellati; Angelo Sala; G Enrico Rovati; Matthieu Leuillier; Sylvain Fraineau; Julie Rondeaux; Victor Hernandez-Olmos; Jan Heering; Daniel Merk; Denys Pogoryelov; Dieter Steinhilber; Stefan Knapp; Jeremy Bellien; Ewgenij Proschak
Journal:  J Med Chem       Date:  2019-09-17       Impact factor: 7.446

3.  Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation.

Authors:  Christophe Morisseau; Aaron T Wecksler; Catherine Deng; Hua Dong; Jun Yang; Kin Sing S Lee; Sean D Kodani; Bruce D Hammock
Journal:  J Lipid Res       Date:  2014-04-27       Impact factor: 5.922

Review 4.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

5.  Heavy chain single-domain antibodies to detect native human soluble epoxide hydrolase.

Authors:  Yongliang Cui; Dongyang Li; Christophe Morisseau; Jie-Xian Dong; Jun Yang; Debin Wan; Martín A Rossotti; Shirley J Gee; Gualberto G González-Sapienza; Bruce D Hammock
Journal:  Anal Bioanal Chem       Date:  2015-07-31       Impact factor: 4.142

6.  Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.

Authors:  Christophe Morisseau; Svitlana Pakhomova; Sung Hee Hwang; Marcia E Newcomer; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2013-05-06       Impact factor: 2.823

Review 7.  Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Authors:  John D Imig
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

8.  Dysregulation of soluble epoxide hydrolase and lipidomic profiles in anorexia nervosa.

Authors:  P B Shih; J Yang; C Morisseau; J B German; A A Scott-Van Zeeland; A M Armando; O Quehenberger; A W Bergen; P Magistretti; W Berrettini; K A Halmi; N Schork; B D Hammock; W Kaye
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

9.  Association Analysis of 14 Candidate Gene Polymorphism with Depression and Stress among Gestational Diabetes Mellitus.

Authors:  Kai Wei Lee; Siew Mooi Ching; Vasudevan Ramachandran; Maiza Tusimin; Noraihan Mohd Nordin; Seng Choi Chong; Fan Kee Hoo
Journal:  Genes (Basel)       Date:  2019-11-30       Impact factor: 4.096

Review 10.  Soluble Epoxide Hydrolase and Brain Cholesterol Metabolism.

Authors:  Michelle Flores Domingues; Natalia Callai-Silva; Angela Regina Piovesan; Celia Regina Carlini
Journal:  Front Mol Neurosci       Date:  2020-01-29       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.